ABBV AbbVie (ABBV) Q1 FY26 earnings call
AbbVie opened FY26 ahead of plan, with the immunology and neuroscience engines more than offsetting managed declines in legacy oncology (Imbruvica) and the ongoing Humira biosimilar runoff, letting management raise the full-year EPS guide even while absorbing a sizable acquired-IPR&D charge. The quarter's signal is durability of the ex-Humira growth algorithm and confidence that Skyrizi and Rinvoq peaks exceed sell-side consensus. Forward, management leaned into an active BD stance across neuroscience, oncology and obesity, and a dense 2026 pipeline calendar — Skyrizi subcu Crohn's, tavapadon,
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.